feedzop-word-mark-logo
searchLogin
Feedzop
homeFor YouUnited StatesUnited States
You
bookmarksYour BookmarkshashtagYour Topics
Trending
Terms of UsePrivacy PolicyAboutJobsPartner With Us

© 2026 Advergame Technologies Pvt. Ltd. ("ATPL"). Gamezop ® & Quizzop ® are registered trademarks of ATPL.

Gamezop is a plug-and-play gaming platform that any app or website can integrate to bring casual gaming for its users. Gamezop also operates Quizzop, a quizzing platform, that digital products can add as a trivia section.

Over 5,000 products from more than 70 countries have integrated Gamezop and Quizzop. These include Amazon, Samsung Internet, Snap, Tata Play, AccuWeather, Paytm, Gulf News, and Branch.

Games and trivia increase user engagement significantly within all kinds of apps and websites, besides opening a new stream of advertising revenue. Gamezop and Quizzop take 30 minutes to integrate and can be used for free: both by the products integrating them and end users

Increase ad revenue and engagement on your app / website with games, quizzes, astrology, and cricket content. Visit: business.gamezop.com

Property Code: 5571

Home / Health / Japan's Maternal Vaccine Uptake Stalls at 11.6%

Japan's Maternal Vaccine Uptake Stalls at 11.6%

18 Jan

•

Summary

  • Maternal RSV vaccination coverage in Japan is only 11.6 percent.
  • High out-of-pocket costs, averaging ¥30,000-¥40,000, deter uptake.
  • Lack of awareness about benefits and the vaccine itself is significant.
Japan's Maternal Vaccine Uptake Stalls at 11.6%

Maternal vaccination against respiratory syncytial virus (RSV) has seen low uptake in Japan, with coverage at just 11.6 percent since its introduction in May 2024. A nationwide survey revealed that high out-of-pocket payments, ranging from 30,000 to 40,000 yen, are a primary barrier for many new mothers. This contrasts sharply with vaccination rates of 30 to 50 percent observed in countries like the United States and Britain.

The survey, conducted by the National Center for Child Health and Development among women who gave birth between July 2024 and August 2025, identified significant awareness issues. Nearly 29 percent of unvaccinated respondents were unaware of the vaccine's benefits, and over 27 percent did not know about the vaccine itself. A strong willingness to vaccinate was expressed, with 77.5 percent stating they would have done so if it were free.

trending

Denver University shelter in place

trending

Christian McCaffrey injured, returns

trending

Bo Nix ankle fracture

trending

Nickelodeon star Kianna Underwood dies

trending

NFL playoffs divisional round

trending

Super Bowl 2026 location

trending

Stefanski hired as Falcons coach

trending

Zach Charbonnet knee injury

trending

Sam Darnold injury status unclear

These findings precede the planned April start of free vaccinations. The research, published in the Journal of Infection and Chemotherapy, also indicated that higher household income and education levels correlate with increased vaccination rates. Experts hope the upcoming free vaccination program will significantly improve these figures and bolster protection for newborns through transplacental antibody transfer.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.
The coverage rate for maternal vaccination against RSV in Japan is 11.6 percent as of a survey conducted around August 2025.
Low coverage is primarily due to high out-of-pocket costs and a lack of awareness about the vaccine and its benefits.
Free vaccinations for pregnant women against RSV are planned to begin in April 2025.

Read more news on

Healthside-arrowGreat Britainside-arrow

You may also like

Nationwide Respiratory Surge: Flu Peaks Decades High

15 Jan • 74 reads

article image

China Flu Cases Drop Four Weeks Straight

14 Jan • 19 reads

article image

Experts Warn Against Limiting RSV Vaccine Access

11 Jan • 41 reads

article image

Covid's Lingering Shadow: Immune Systems Weakened?

11 Jan • 61 reads

article image

FDA Probes Infant RSV Drugs Amid Safety Review

9 Dec, 2025 • 177 reads

article image